Selective laser trabeculoplasty versus eye drops for first line treatment of exfoliation ocular hypertension or glaucoma: a randomised clinical trial
Key facts
- Where
- Helsinki, FinnországSee the site
- Phase
- 4. fázis
Where in Finnország
- HUS-YhtymaeHelsinki, FinnországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- HUS-Yhtymae
- Trial code
- EU 2024-520083-33-00
- Record updated
- 2024. december 19.
- Original description
The main objective of the trial is to show the equilance in efficacy of SLT laser treatment compared to medical therapy as a primary therapy in exfoliation glaucoma.Read full original descriptionShow less
The main objective of the trial is to show the equilance in efficacy of SLT laser treatment compared to medical therapy as a primary therapy in exfoliation glaucoma.
Inclusion: Informed consent; Age of 50 –100 years; Possibility to attend 12 months of period; Exfoliation; Newly diagnosed exfoliation glaucoma by EGS (European glaucoma society) guidelines or ocular hypertensio TA 24 mmHg or more; Eye pressure less than 35 mmHg.
Exclusion: Previous intraocular operation excluding uncomplicated cataracta surgery 1 year ago or earlier; Serious other medical condition preventing participation in the trial; Other active eye disease (active uveitis, clinical significant macular edema, wet AMD, proliferative diabetic retinopathy, intraocular tumor, intraocular injections, IOL luxation); Advanced glaucoma; Participating in other clinical trial; Target IOP less than 15; Starting eye pressure 35 or more; Visual acuity 0.2 or worse; Angle closure; Unable to use eye drops; Significant cataract.